ClinicalTrials.gg
SuspendedNCT06531460Updated Nov 13, 2026

Nutritional Therapy Enriched With Omega-3 in Patients With Lung Resection

An interventional study of Fish oil enteral supplementation and Fish oil oral supplementation in Lung Cancer and Surgery, sponsored by National Institute of Respiratory Diseases, Mexico. Suspended at 1 site in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by National Institute of Respiratory Diseases, Mexico · Not applicable, Interventional, and Prevention

How we know

Why this study was suspended
The clinical trial was discontinued due to a lack of coordination among the departments involved in scheduling and providing the required surgical time. Consequently, it was not possible to perform the surgical procedure within the established timefr
Updated Nov 13, 2026Now SuspendedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
310
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Lung Neoplasms with a site in Mexico — 14 open to participants now, 21 under way, 13 of them phase 3. Lung Neoplasms · Mexico.

Planned enrollment
28th of 40
310 · median 430
Started
2024
with 4 others
No phase
3 of 52
none open now
Registered
44th of 52
by date

Among the 52 studies in Lung Neoplasms with a site in Mexico, this one is the 28th largest by planned enrollment of the 40 interventional ones that give a count, is one of 5 that started in 2024, is one of 3 with no phase, and was the 44th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

14 of the 52 studies in Lung Neoplasms with a site in Mexico are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Lung Neoplasms with a site in Mexico, or all of them as a file.
02

Study summary

The aim of this study is to analyze the effect of enriched formula with omega-3 in the 30-day incidence infection and inflammatory response following lung resection surgery in lung cancer patients.

03

Conditions studied

  • Lung Cancer
  • Surgery

Keywords

  • lung cancer
  • omega-3
  • prehabilitation nutrition
  • perioperative nutrition
  • infections
  • inflammation response
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Lung cancer diagnosis
  • Elective surgery for lung resection schedule at least four days before surgery
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • Acute or chronic organ failure as hepatic or renal insufficiency
  • Patients with fish-allergy
  • History of any surgery within 3 months
  • patients
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
310 participants (estimated)

Study arms

  • Experimental
    Experimental enteral nutrition

    Patients admitted to the hospital at least three days before surgery Use of an enteral feeding tube to administer enriched enteral formula

    Dietary Supplement: Fish oil enteral supplementation

  • Experimental
    Experimental oral nutrition

    Patients admitted one day before surgery. Home-self administration of enriched enteral formula three days before surgery

    Dietary Supplement: Fish oil oral supplementation

  • Other
    Standard enteral nutrition

    Patients admitted to the hospital at least three days before surgery Use of an enteral feeding tube to administer standard enteral formula

    Dietary Supplement: Enteral nutrition without fish oil

  • Other
    Standard oral nutrition

    Patients admitted one day before surgery. Home-self administration of standard enteral formula three days before surgery

    Dietary Supplement: Oral nutritional supplement without fish oil

Interventions

  • Dietary supplementFish oil enteral supplementation

    Omega-3 (4.2 g), administered through an enteral feeding tube, three days before surgery

  • Dietary supplementFish oil oral supplementation

    Omega-3 (4.2 g), orally administered enriched nutritional formula, drinking at home three days before surgery

  • Dietary supplementEnteral nutrition without fish oil

    Enteral formula without omega-3 administered through an enteral feeding tube, three days before surgery

  • Dietary supplementOral nutritional supplement without fish oil

    Oral nutritional supplement without omega-3 orally administered, drinking at home three days before surgery

06

What researchers measure

Primary outcomes

  1. 30-day incidence infection

    Incidence of infectious complications after surgery diagnosed using any of these criteria: Infection of surgery wound confirmed by culture Infection confirmed by blood culture Pneumonia developed after surgery confirmed by chest x Ray.

    Time frame: 30-day incidence infection following lung resection in lung cancer patients.

Secondary outcomes

  1. Changes in prostaglandin E2

    Measured in serum sample made by Enzyme-linked immunosorbent assay (ELISA).

    Time frame: At the beginning of nutritional therapy and at day-4 following surgery

  2. Changes in Interleukin-6

    Measured in serum sample made by Enzyme-linked immunosorbent assay (ELISA).

    Time frame: At the beginning of nutritional therapy and at day-4 following surgery

  3. Changes in Tumor Necrosis Factor Alpha (TNF-α)

    Measured in serum sample made by Enzyme-linked immunosorbent assay (ELISA).

    Time frame: At the beginning of nutritional therapy and at day-4 following surgery

  4. Number of participants with therapeutic antibiotics prescription

    Frequency of therapeutic antibiotics prescription will be collected from medical records and medication administration registers.

    Time frame: During the hospital stay until 30-day

  5. Hospital lenght of stay

    Number of calendar days that elapsed since hospital admission to the day of hospital discharge

    Time frame: During the hospital stay until 90-day

07

Study locations

1 site
  • National Institute of Respiratory Diseases
    Mexico City, 14080, Mexico
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Dec 2026, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2024
First posted
Aug 1, 2024
StartActual
Jul 25, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jul 30, 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Suspended The clinical trial was discontinued due to a lack of coordination among the departments involved in scheduling and providing the required surgical time. Consequently, it was not possible to perform the surgical procedure within the established timefr
changed Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Recruiting→Suspended
    Why stopped The clinical trial was discontinued due to a lack of coordination among the departments involved in scheduling and providing the required surgical time. Consequently, it was not possible to perform the surgical procedure within the established timefr
    + 4 other changes: verification date, date precision, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06531460
Lead sponsor
National Institute of Respiratory Diseases, Mexico
Responsible party
Ivan Armando Osuna Padilla (Clinical Nutrition Manager, National Institute of Respiratory Diseases, Mexico) — Principal investigator
First posted
Aug 1, 2024
Start date
Jul 25, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Ivan A Osuna-Padilla, PhD
principal investigator · Instituto Nacional de Enfermedades Respiratorias

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion